Respiratory syncytial virus prevention in children with congenital heart disease: who and how?
Introduction
Respiratory syncytial virus (RSV) is a common pathogen in causing acute upper respiratory infection in all ages. RSV is a cause of frequent respiratory infection for children in particular. Most of the children are infected at least once by RSV by the age of 2 and symptomatic recurrent infections are also common even within one season 1) . In children under the age of 2 with high risk factors, severe lower respiratory infection may develop 2) . Risk factors that may cause prevention in CHD patients have been rapidly progressing since the development of palivizumab 4) . Palivizumab (MEDI493) is a humanized monoclonal antibody to F glycoprotein and has neutralizing and fusion inhibitory effect against RSV 5) . Studies proving the efficacy of RSV prevention through palivizumab in CHD patients have been developing, and multinational, randomized, doubleblind trials have proved its safety and efficacy 6) . This study included patients who were 1 year old or younger, with hemodynamically significant CHD. Hemodynamically significant CHD was defined as increased pulmonary blood flow with or without cyanosis, pulmonary venous congestion, pulmonary hypertension, and remaining residual hemodynamic abnormality after surgical correction, and these patients were recommended immunoprophylaxis of RSV infection. In a recently published study on RSV infection and hospitalization risk factors in CHD patients, Down syndrome and cardiomyopathy patients with RSV infection were also candidates who needed intensive care as well as the above mentioned patients 7) . Through studies that have been conducted, the American Academy of Pediatrics (AAP) has included children with bronchopulmonary dysplasia, prematurity, hemodyanamically significant cyanotic and acyanotic CHD patients as high risk group for RSV infection, and expanded the age limit to 2 years of age or younger 2) . Because hemodynamically significant CHD patients show severe progress, prevention of RSV infection is recommended.
Prevention for RSV infection 1. General prophylaxis
The primary prevention of RSV infection is minimizing exposure to RSV. Even after an exposure, minimizing recurrent exposure can reduce infection. Other preventive measures include the following: 1) Reduce exposure to cigarette smoke 2) Restrict participation of child care in high risk patients during RSV season. 3) Encourage hand washing in all circumstances. Families with high risk patients who have older siblings are especially in need of intensive hand washing 8) . Because RSV is highly contagious, special caution is needed for infants with CHD who are hospitalized 9) . Therefore in high risk patients for RSV infection who are hospitalized need intense primary prevention, such as hand washing of medical staff, wearing a surgical mask and eye protection 10) . These efforts should be made more vigorously and thoroughly during RSV season.
Immunoprophylaxis 1) RSV immunoglobulin
Immunoglobulin for RSV (RSVIVIG) was developed and first used in 1996 (RespiGam Ⓡ , MedImmune, LLC, Gaithersburg, MD, USA). RSVIVIG was first developed for preterm infants and it was contraindicated at first for patients diagnosed as CHD. Through controlled trial, hospitalization due to RSV infection was proven to decrease up to 41-63% after use of RSVIVIG 11) . However, there was a possibility that the use of RSVIVIG in children diagnosed as CHD increased the morbidity and mortality 12) . Also, because RSV IVIG is a type of human blood product, there was a possibility of increased blood borne infection and interference of live vaccines such as measles, mumps, and rubella (MMR). Therefore the product was not used since the year 2003.
(1) Palivizumab Palivizumab (Synagis Ⓡ , MedImmune, LLC, Gaithersburg, MD, USA) was developed by grafting the six complementarity determining regions (CDRs) of mouse MAb to human frameworks 5) . Palivizumab has received US FDA license in 1998, and it has been used to prevent serious lower respiratory tract infection caused by RSV infection ever since. The safety and efficacy was proven even for highrisk patients since then and currently, it is recognized as the gold standard in RSV prevention. Even in times when RSVIVIG was being used, palivizumab was preferred because of the easy method of administration (intramuscular injection) and lower interference to MMR and varicella vaccine. Since RSVIVIG is no longer available, palivizumab is the only licensed product for prevention of RSV infection. Infants diagnosed as CHD are considered as highrisk group for severe lower respiratory infection due to RSV infection, therefore immunoprophylaxis is recommended using palivizumab 2, 6, 7, 1316) . Patients with hemodynamically significant cyanotic and acyanotic CHD should start administration of palivizumab before the RSV season starts. Commonly recommended administration dose for palivizumab is 15 mg/kg, intramuscularly once per month for a maximum of five doses 2, 3) . For most of the patients, the compliance under this schedule is tolerable. However, for the few noncompliant patients, homebased program for scheduled palivizumab administration may be helpful in reducing hospitalization caused by RSV infection 17) . Hemodynamically significant CHD is described in Table 1 18) . In these CHD infants categorized as highrisk group for RSV infection, if RSV prevention is not conducted effectively, mortality after hospitalization is known to increase 3) . Particularly in these vulnerable infants who are less than 6 months old, the result of RSV infection is more catastrophic. These patients are more prone to hospitalization in the intensive care unit and they have higher possibility of ventilator care 19) . The blood level of palivizumab after operation under cardiopulmonary bypass may drop by 58%, therefore CHD patients who need continuous prevention for RSV needs to administer palivizumab (15 mg/kg) soon after operation 2) . Through a randomized controlled study the effectiveness of palivizumab for RSV infection in CHD patients has been pro ven 4) . In this study, patients who were administered palivizumab were hospitalized less often (5.3 versus 9.3%), were in need of oxygen administration less often (178 versus 658), and the total of hospitalization days were reduced (367 versus 876). Therefore, the use of palivizumab in prevention of RSV infection in CHD patients can be costeffective in both the medical aspect of the patients as well as the socioeconomic aspect 2022) . Although there are many studies reporting the advantages in socioeconomic aspects after prophylaxis of RSV infection in CHD patients under the age of 2 years, Korean medical insurance restricts the use of palivizumab to infants of hemodynamically significant CHD patients under the age of 1 year, unfortunately. Further studies and proposals in this matter are imminent. Complications after administration of palivizumab are very rare (<1 per 100,000 recipients), but there was a report of severe hypersensitivity 18) . However, in a study reporting on the safety of palivizumab, there were no significant complications reported in the 2 years that palivizumab was administered, which may prove that it is safe to use 23, 24) . In some studies, there were reports on RSV infection resistant to palivizumab 25) . However, there was a report observing 458 infants who were administered with palivizumab without any mutation, which may also prove that palivizumab is effective in RSV infection prophylaxis without much complication 26) . Recently, the idea that palivizumab can be used not only for prophylaxis but also for treatment has been mentioned. However, further study for treatment effect of palivizumab to RSV in a large population is warranted 27, 28) .
Gaithersburg, MD, USA) is a second generation monoclonal antibody for RSV. It is known to be more potent than palivizumab to RSV infection in highrisk patients. Motavizumab has passed the US FDA biologic license application in January of 2008 and is under a large scale clinical study 29, 30) .
2) RSV vaccines
Vaccination for RSV infection has not yet been developed. Theo retically, vaccination is a more effective long term preventive method than passive immunization such as palivizumab. Therefore there were numerous efforts trying to develop live attenuated, viral and bacterial vectored, and adjuvant subunit vaccines 3133) . However, development of effective RSV vaccines is not fulfilled even under these massive efforts. The interest in developing RSV vaccination is continuously increasing, and recently acquiring immunity of RSV using mu cosal and systemic immune response by nanoparticle vaccine is under study 34) . However, there are many remaining limitations in developing an effective and safe RSV vaccine 35, 36) .
Conclusion
Patients, under the age of 2 years, diagnosed as hemodynamically significant CHD are highrisk group for serious RSV infection. Immunoprophylaxis in these highrisk patients are highly recom mended. The proven safe recommended administration dose for immunoprophylaxis of RSV infection is injecting 15mg/kg of palivizumab, intramuscularly once per month for a maximum of five doses. Motavizumab as well as RSV vaccine, currently under development, may contribute to RSV prevention in the future.
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